Gulf War Illness Clinical Trial
Official title:
Q10 for Gulf War Veterans
Goal: The investigators propose to test whether giving the supplement coenzyme Q10 (Q10)
improves symptoms and subjective health in Gulf War veterans (GWV) with chronic,
multi-symptom health problems.
Rationale: Direct empirical evidence, in groups that are not GWV, has supported benefit of
Q10 to many of the symptoms that GWV are at heightened risk of experiencing - such as
fatigue, muscle pain, and cognition, which are syndrome-defining conditions. In addition, Q10
has also been reported to benefit other symptoms arising at increased rates in GWV, including
headaches, sleep disturbances, and breathing problems. This provides a strong rationale for
testing whether Q10 will have similar benefit to these symptoms in GWV.
Method: 46 GWV with chronic health problems will participate.The design is a randomized,
double-blind, placebo-controlled crossover study. Each subject will be "crossed over" between
Q10 and an identical placebo, receiving each agent twice, for 3.5 month periods. In one of
the Q10 phases, a lower dose of Q10 will be used - 100mg three times a day; while in one a
higher dose will be used - 300mg three times a day. Neither subjects nor investigators will
know which substance each subject is receiving in which phase. Subjects will be randomly
assigned to one of four crossover orders.
Assessments: Assessments will include subjective quality of life; symptoms that are "syndrome
defining" for Gulf War illness (like fatigue and muscle problems); and other symptoms and
conditions reported to occur more commonly in GWV (like sleep problems). Analyses will show
whether Q10 led to improvements when compared to placebo; whether higher Q10 doses improved
outcomes more than lower doses; and whether people with certain symptoms or characteristics
get more benefit than people with other symptoms or characteristics.
Goal: To determine, via a double-blind placebo-controlled crossover study, whether coenzyme
Q10 (Q10) administration reduces symptoms and improve subjective health in Gulf War veterans
(GWV).
Rationale: In a number of settings, studies have reported benefits of Q10 to fatigue, muscle
pain and cognition, "syndrome" defining symptoms in GWV. It has also been reported to improve
a range of other symptoms and conditions that arise at increased rates in GWV. Additionally
Q10 defends against mechanisms that may play a role in health problems in GWV. For these
reasons, a study evaluating benefits by Q10 to symptoms and quality of life in symptomatic
GWV is merited.
Subjects: 46 GWV meeting Center for Disease Control (CDC) and Kansas criteria for "Gulf War
illness." Design: Randomized, placebo-controlled, double-blind crossover study. Intervention:
Coenzyme Q10 at 100mg three times a day (tid) or 300mg tid or matching placebo for 3.5 ± 0.5
month periods.
Primary Outcome: Subjective health; syndrome defining symptoms (fatigue, muscle pain, muscle
strength; and cognition).
Secondary Outcomes: A variety of secondary outcomes will be assessed including other symptoms
reported to be elevated in GWV; markers of oxidative stress; and dose-response.
Analyses: Nonparametric and secondarily parametric analyses will compare effects of Q10 vs
placebo; and of higher dose vs lower dose Q10 on primary and secondary endpoints. Possible
effect modification (differential benefit) based on factors such as oxidative state and Q10
serum concentration will be explored through regression analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04254627 -
TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset
|
Phase 1 | |
Terminated |
NCT02011542 -
Probiotic (VSL #3) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078530 -
Probiotic (Visbiome) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT04058275 -
"Immunomodulation in GWI (Phlebotomy)"
|
||
Recruiting |
NCT04255498 -
Understanding GWI: Integrative Modeling
|
Phase 1 | |
Completed |
NCT02782780 -
Cognitive Behavioral Therapy for Insomnia for Gulf War Illness
|
N/A | |
Recruiting |
NCT02983734 -
D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)
|
Phase 2 | |
Recruiting |
NCT05972291 -
Mechanisms of Gulf War Illness
|
N/A | |
Recruiting |
NCT04046536 -
rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI)
|
N/A | |
Recruiting |
NCT04182659 -
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
|
N/A | |
Recruiting |
NCT05377242 -
Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI
|
N/A | |
Recruiting |
NCT05675878 -
Confirmation of Diet as a Treatment for Gulf War Illness
|
Phase 3 | |
Recruiting |
NCT05736146 -
Validating Gulf War Illness Blood Biomarkers
|
||
Not yet recruiting |
NCT05820893 -
Resistant Potato Starch to Alleviate GWI
|
Phase 2 | |
Terminated |
NCT01846182 -
Research Examining Gulf War Illness in Our Nations Service Members
|
Phase 2 | |
Active, not recruiting |
NCT05252949 -
OEA for Targeting Lipid Metabolism in GWI
|
N/A | |
Completed |
NCT02378025 -
Treating Chronic Pain in Gulf War Illness
|
N/A | |
Completed |
NCT02865460 -
Coenzyme Q10 Phase III Trial in Gulf War Illness
|
Phase 3 | |
Completed |
NCT02909686 -
Effects of Botanical Microglia Modulators in Gulf War Illness
|
N/A | |
Completed |
NCT01291758 -
Exercise in Gulf War Illness (GWI)
|